Evidence map›Paper›PMID 40394531›Full record

ArticleBMC endocrine disorders2025

Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples.

Thi Nhung Nguyen, Zhanna Mussazhanova, Hirokazu Kurohama, Van Dong Hoang, Ngoc Ha Le, Thi Minh Hanh Ngo, Van Phu Thang Nguyen, Katsuya Matsuda, Yuki Matsuoka, Katsiaryna Tratsiakova and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Thi Nhung Nguyen *Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Zhanna Mussazhanova *Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Hirokazu KurohamaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Van Dong HoangMedical Oncology Clinical Trial Unit Fiona Stanley Hospital, 11 Robin Warren Drive, Murdoch, WA, 6150, Australia.
Ngoc Ha LeDepartment of Nuclear Medicine, 108 Military Central Hospital, Ha Noi, Vietnam.
Thi Minh Hanh NgoDepartment of Pathology, 108 Military Central Hospital, Ha Noi, Vietnam.
Van Phu Thang NguyenDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Katsuya MatsudaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Yuki MatsuokaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Katsiaryna TratsiakovaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Thi Ngoc Anh NguyenDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Yerkezhan SailaubekovaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Thi Phuong NguyenDepartment of Nuclear Medicine, 108 Military Central Hospital, Ha Noi, Vietnam.
Minh Son LeDepartment of Pathology, 108 Military Central Hospital, Ha Noi, Vietnam.
Masahiro NakashimaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan. moemoe@nagasaki-u.ac.jp.ORCID http://orcid.org/0000-0002-9036-8735

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough papillary thyroid carcinomas (PTC) are usually indolent in nature and clinically controllable, two-thirds of metastatic diseases become radioactive iodine-refractory (RAI-R). This study aimed to determine the role of pathological features, BRAF

methodsThis cross-sectional study included 174 cases of locoregional recurrent PTC, including 135 and 39 RAI-R and RAI-avid (RAI-A) cases, respectively. Logistic regression analyses were used to evaluate the associations between pathological features, mutations, and RAI-R with tissues from recurrent lesions.

resultsLoss of polarity/loss of cell cohesiveness (LOP/LCC) component was exclusively observed in recurrent cancers in the RAI-R group. RAI-R was associated with BRAF

conclusionsRAI-R PTC cases were independently associated with BRAF

Indexed as

Biomarkers, TumorIodine RadioisotopesMutationNeoplasm Recurrence, LocalThyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedCross-Sectional StudiesDNA Mutational AnalysisFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisBiomarkers, TumorBRAF protein, humanIodine RadioisotopesProto-Oncogene Proteins B-rafTelomeraseTERT protein, humanBRAF V600EMitosisRadioactive iodine refractoryRecurrent papillary thyroid carcinomaTall cellTERT promoter

Identifiers

PMID40394531
PMCPMC12090457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.